- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectis (ALCLS)
Assess today's live Cellectis (ALCLS) share price, performance and insights using our live Paris: ALCLS stock exchange data.
Analyse the historical data and Cellectis share price performance charts on this page. Our technical summary section provides analysis on Cellectis share price buy/sell indicators using real-time data (or discuss the Cellectis (ALCLS) stock price today with other investors in the Cellectis EPA share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current EPA ALCLS share price (ISIN: FR0010425595) to enhance your trading decisions with our free investment tools and resources.
What Is the Cellectis Share Price Today?
The Cellectis share price today is 1.54.
What Is the Stock Symbol for Cellectis
The stock symbol (or 'ticker') for Cellectis is "ALCLS."
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Paris stock exchange.
Is Cellectis a Good Stock to Buy?
Determining whether Cellectis—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Cellectis share price performance charts on this page. Our technical summary section provides analysis on Cellectis share price buy/sell indicators using real-time data (or discuss the Cellectis (ALCLS) stock price today with other investors in the Cellectis EPA share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current EPA ALCLS share price (ISIN: FR0010425595) to enhance your trading decisions with our free investment tools and resources.
What Is the Cellectis Share Price Today?
The Cellectis share price today is 1.54.
What Is the Stock Symbol for Cellectis
The stock symbol (or 'ticker') for Cellectis is "ALCLS."
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Paris stock exchange.
Is Cellectis a Good Stock to Buy?
Determining whether Cellectis—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
1.54
-0.05(-3.39%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.53
1.61
52 wk Range
1.41
3.03
ALCLS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.531.61
52 wk Range
1.413.03
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALCLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Cibus announces public offering of Class A stock
- Investing.com
- Cibus sets price for 3 million share public offering
- Investing.com
- Cibus sets price for 3 million share public offering
- Investing.com
- Cibus announces public offering of Class A stock
- Investing.com
Cellectis Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Compare ALCLS to Peers and Sector
Metrics to compare | ALCLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALCLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −1.6x | −0.6x | |
PEG Ratio | −0.05 | −0.09 | 0.00 | |
Price/Book | 1.3x | 2.2x | 2.6x | |
Price / LTM Sales | 4.6x | 6.1x | 3.1x | |
Upside (Analyst Target) | - | 173.3% | 51.5% | |
Fair Value Upside | Unlock | 22.4% | 8.4% | Unlock |
Earnings
Latest Release
Nov 04, 2024
EPS / Forecast
-0.211 / -0.2177
Revenue / Forecast
16.56M / 4.94M
People Also Watch
FAQ
What Is the Cellectis (ALCLS) Stock Price Today?
The Cellectis stock price today is 1.54
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Paris stock exchange.
What Is the Stock Symbol for Cellectis?
The stock symbol for Cellectis is "ALCLS."
What Is the Cellectis Market Cap?
As of today, Cellectis market cap is 154.14M.
What is Cellectis Earnings Per Share?
The Cellectis EPS is -1.03.
What Is the Next Cellectis Earnings Date?
Cellectis will release its next earnings report on 26 Feb 2025.
From a Technical Analysis Perspective, Is ALCLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.